operative characteristics were: age: 61 (38-83), QoL: 8.12 (2.5-10), UDI question 3 answers 2 or 3 in 92% VLPP: 58 cm H20 (25-120). Prior surgeries were: slings (4), bladder neck suspension (21), urethrolysis (2), diverticulum repair (2), urethrovaginal fistula repair (2). Mean volume of collagen injected was 5.5cc (2.5-7.5). Baseline post- operative US collagen volume was 2.6cc (.8-4.8), mean QoL 4.9 (1-10), and UDI question 3: 2 or less in 60% of patients. 93% considered themselves clinically im- proved or cured. Seventeen/31 required only one injection with an initial US vol- ume of 2.8cc (0.8-4.2) and symmetric con- figuration in 83%. Eight had 1 or 2 more injections because of an asymmetric con- figuration (75%) and/or low volume. De- spite a good collagen volume of 3.2cc (2-4.3), 6 with persistent SUI underwent a pubovaginal sling. Eight of the 25 patients requiring only collagen had stable colla- gen volume over 2 years without reinjec- tion. Conclusions: Collagen injection is a via- ble option with satisfactory results for pa- tients with persistent SUI after a urethral or peri-urethral surgery. Based on 3D US, it is a durable injectable which does not compromise further therapies. MP-10.12 How does functional capacity and first sensation during cystometrogram relate to nocturia? Steele SS, Gajewski JB Department of Urology, Dalhousie Uni- versity, Halifax, NS, Canada Objectives: The relationship between bladder capacity and first sensation of bladder filling during CMG as it relates to patient reported nocturia has been poorly explored . In this study we investigated the relationship between patient reported nocturia versus maximum cystometric ca- pacity (MCC) and first sensation of blad- der filling (FSBF). Methods: We have electronic charts on all patients who have undergone Conven- tional Urodynamic Studies from 1996-2006 at our institution contained in an urody- namics (UD) data base. Using this data base MCC and volume at FSBF were cross- referenced with the degree of nocturia reported by patients. The amount of noc- turia was graded from 0 to 3. With 0, 1, 2 and 3 corresponding to 0 times/night, 1-2 times/night, 3-4 times/night and 4 times/night respectively. Mean and stan- dard deviation for MCC and volume at FSBF were then determined for each level of nocturia. A one-way ANOVA (p0.05) was applied to each level of nocturia to determine statistical significance. In addi- tion, those individuals describing no noc- turia and those reporting nocturia were compared to determine statistical signifi- cance using a two tailed unpaired t test. Results: There were 3499 consecutive patients identified in the UD database. The mean MCC for nocturia 0, 1, 2, and 3 were 338.9, 294.9, 258.7 and 239.9 re- spectively. The mean volume at FSBF for nocturia 0, 1, 2 and 3 were 216.8, 177.5, 161.5 and 150.8 respectively. A statistical significance was observed between all nocturia levels, as well as between those reporting nocturia and those reporting no nocturia for both MCC and volume at FSBF. Conclusion: This is the first large study to demonstrate that patients with nocturia have a significant decrease in maximum functional capacity and earlier first sensa- tion of bladder filling as their nocturia worsened. This suggests that decreased bladder capacity as measured by MCC, plays a major role in patient reported noc- turia. MP-10.13 Use of the adjustable continence therapy for the treatment of recurrent female urodynamic stress urinary incontinence Kocjancic E, Crivellaro S, Favro M, Frea B Department of Urology, University Hospi- tal Udine, Pasian di Prato, Italy Objectives: The Adjustable Continence Therapy (ACT®) has been developed to increase urethral coaptation in females with Intrinsic Sphincter Deficiency (ISD). We evaluated the procedure and assessed its mid-long term follow up. Material and Methods: The ACT device consists of two silicone balloons placed para-urethrally in the vesico vaginal space at the level of bladder neck, each attached to an injectable titanium port placed in the labia majora, enabling postoperative adjustment. Patients were evaluated using daily pad count; Incontinence Quality of Life (IQOL) questionnaire and Visual Ana- logue Score (VAS) at baseline and at peri- odically post operatively. Results: Forty-ninepatients, mean ages 62.59 (range15-86) years, were implanted with ACT. Mean follow up was 40.1 months (range 6-71). All patients had un- dergone at least one previous pelvic sur- gery. Operative time was 20.3 mins (range 10-30 mins)with minimal blood loss. No postoperative analgesia was required and all patients were able to void within 24 hours. Eighteen patients (36%) did not require any post operative adjustments. The remainder required singular or multi- ple adjustments (range 1-11). Complica- tions included labial haematomas in 3 pre menopausal patients within 24 hours of implantation which spontaneously reab- sorbed without intervention. Two (4%) patients had portal erosions due to poor positioning. Device removal resulting from migration was seen in (12%) patients and urethral erosion in (2%) patient. Addi- tionally (3.6%) balloons were explanted due to device failure. Pre operative sen- sory urgency seen in 14.3% patients was unresolved post operatively. Furthermore 12.2% patients reported denovo urgency post implantation. In all 6 patients this was transient and resolved within 3 months without the need for anticholin- ergic medication. Conclusion: Implantation of the ACT balloons is safe and effective. The minimal dissection required for balloon insertion makes this an ideal technique in failed previous incontinence surgeries. MP-10.14 Efficacy and tolerability of the OROS- based oxybutynin extended-release formulation (Lyrinel) in patients with neurogenic detrusor overactivity Riedasch G, Reitz A Neuro-Urology, Spinal Cord Injury Cen- ter, Orthopedics University Hospital, Hei- delberg, Germany Introduction: To study the efficacy and tolerability of the OROS-based oxybutynin extended-release formulation (Lyrinel) in patients with neurogenic detrusor overac- tivity. Methods: 29 patients presenting with spinal cord injury and neurogenic detru- Table 1. MP-10.13 Pre(n49) 12 month (n38) 24 month (n33) 36 month (n28) 48 month (n23) IQoL 30 71 (SD19.04) 74 (SD 30.5) 86 (SD 24.2) 93 (SD 21.8) Pads 5.4 1.2 (SD 2.87) 1.1 (SD 3.38) 0.7 (SD 2.59) 0.5 (SD 2.79) VAS 79% 83% 85% 84% MODERATED POSTER SESSIONS UROLOGY 70 (Supplment 3A), September 2007 89